Cyprium

New York, United States Founded: 2017 • Age: 9 yrs
Therapeutics for rare pediatric copper-related diseases are developed.

About Cyprium

Cyprium is a company based in New York (United States) founded in 2017 by Lung S Yam.. Cyprium has raised $7 million across 1 funding round. Cyprium offers products and services including CUTX-101 and AAV-ATP7A. Cyprium operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

  • Headquarter New York, United States
  • Founders Lung S Yam
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Cyprium Therapeutics Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $7 M (USD)

    in 1 rounds

  • Latest Funding Round
    $7 M (USD), Series A

    Oct 05, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cyprium

Cyprium offers a comprehensive portfolio of products and services, including CUTX-101 and AAV-ATP7A. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Investigational treatment for Menkes disease using copper histidinate.

Gene therapy targeting Menkes disease and copper disorders.

Funding Insights of Cyprium

Cyprium has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Series A round of $7 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $7.0M
  • First Round

    (05 Oct 2021)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2021 Amount Series A - Cyprium Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Cyprium

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cyprium

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cyprium Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cyprium

Cyprium operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Provider of cell therapies to treat cancer and hematologic conditions
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Cyprium

When was Cyprium founded?

Cyprium was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Cyprium located?

Cyprium is headquartered in New York, United States. It is registered at New York, New York, United States.

Who is the current CEO of Cyprium?

Lung S Yam is the current CEO of Cyprium. They have also founded this company.

Is Cyprium a funded company?

Cyprium is a funded company, having raised a total of $7M across 1 funding round to date. The company's 1st funding round was a Series A of $7M, raised on Oct 05, 2021.

What does Cyprium do?

Cyprium was founded in 2017 in New York, United States, as a biotechnology company focused on rare pediatric diseases. Operations center on copper metabolism disorders, particularly Menkes disease. The lead product, CUTX-101 (copper histidinate), is being advanced alongside AAV-ATP7A gene therapy for treatment. Development efforts target unmet needs in these conditions through targeted therapeutics.

Who are the top competitors of Cyprium?

Cyprium's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

What products or services does Cyprium offer?

Cyprium offers CUTX-101 and AAV-ATP7A.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available